You can call MIRG.org toll-free at (1-888-802-6376)
Clinical Trial Results
Below are results from recent mesothelioma and or other cancer clinical
trials. For more information on these clinical trial results please visit the
source's website.
—Bevacizumab Improves Survival in Metastatic Colorectal Cancer
Patients with newly diagnosed metastatic colon
cancer who received the therapeutic agent bevacizumab (Avastin™) along with
the chemotherapy combination known as IFL had substantially longer overall
survival times than patients who received IFL but with a placebo instead
of bevacizumab. With these results, bevacizumab becomes the first anti-angiogenesis
agent to prove effective in a randomized Phase III trial.
Learn more>>
Click here to
go back to the current clinical trials page
***Please note that the clinical trials listed on this page have additional specific requirements. Call contacts listed for each trial for more detailed information.
